A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

• Status: Completed
• Trial end date: 2016-07-28

Summary

The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).

• Phase: Phase 3

Details

• Lead Sponsor: Janssen Scientific Affairs, LLC
• Collaborator: Bayer
• Treatments: Aspirin; Clopidogrel; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Ticlopidine; Vitamin K; Vitamins